6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

April 8, 2020

Commission File Number: 001 - 38178

Zealand Pharma A/S

(Exact Name of Registrant as Specified in Its Charter)

Sydmarken 11

2860 Søborg (Copenhagen)
Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x            Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨

Furnished as Exhibit 99.1 to this Report on Form 6-K is a company announcement of Zealand Pharma A/S or the Company, dated April 8, 2020, confirming receipt of information on transactions in the Company’s shares or related securities by persons discharging managerial responsibilities and/or their closely associated persons.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Zealand Pharma A/S
By:	/s/ Matthew Dallas
	Name:	Matthew Dallas
	Title:	Chief Financial Officer

Date: April 8, 2020

2

EXHIBIT INDEX

Exhibit No.	Description
99.1	Company announcement dated April 8, 2020
99.2	Notification of sale of shares: A. Steensberg 2020Apr02
99.3	Notification of sale of shares: A. Steensberg 2020Apr03
99.4	Notification of sale of shares: A. Steensberg 2020Apr06

3

EX-99.1

Exhibit 99.1

 

Company announcement – No. 18 / 2020

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Copenhagen, April 8, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78) has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.

Please see the attached files.

For further information, please contact:

Zealand Pharma Investor Relations

+45 50 60 38 00 investors@zealandpharma.com

Lani Pollworth Morvan, Investor Relations and Communication

lpm@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes clinical license collaboration with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.

Zealand is based in Copenhagen (Søborg), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.

EX-99.3

Exhibit 99.3

Template for notification and public disclosure of transactions by persons discharging manage-rial responsibilities and persons closely associated with them 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Adam Steensberg 2.       Reason for the notification a) Position/status EVP, Chief Medical and Development Officer in Zealand Pharma A/S b) Initial notification/Amend- Initial notification ment 3.       Details of the issuer, emission allowance market participant, auction platform, auctioneer or auc- tion monitor a) Name Zealand Pharma A/S, CVR-no. 20045078 b) LEI¹ 549300ITBB1ULBL4CZ12 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial Shares instrument, type of instru- ment Identification code DK0060257814 b) Nature of the transaction Sale of shares c)       Price(s) and volume(s) Price(s) Volume(s) DKK 215,9 18.158 d)       Aggregated information - Aggregated volume DKK 3.920.584,57 - Price e) Date of the transaction 03 April 2020 f) Place of the transaction Nasdaq Copenhagen A/S